Press release
The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022 | Major Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
respiratory syncytial virus infections market
The Respiratory Syncytial Virus Market research report conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The Respiratory Syncytial Virus market driving factors, market overview, industry volume, and market share are also highlighted in this Respiratory Syncytial Virus Market report analysis.
Key Takeaways from the Respiratory Syncytial Virus Market Report
• In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.
• In 2022, as per the severity of Respiratory Syncytial Virus infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of Respiratory Syncytial Virus in the US, respectively.
• The market size of the Respiratory Syncytial Virus in the 7MM was observed to be ~USD 1,200 million in 2022.
• The leading Respiratory Syncytial Virus Companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
• Promising Respiratory Syncytial Virus Pipeline Therapies include Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others
Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approaches, Treatment Practices, and Forecasted Epidemiology @ Respiratory Syncytial Virus Market Size- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Overview
Respiratory Syncytial Virus is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. Respiratory Syncytial Virus belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human Respiratory Syncytial Virus, bovine Respiratory Syncytial Virus, and murine pneumonia virus.
Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM
• Respiratory Syncytial Virus Patient Pool
• Respiratory Syncytial Virus Forecasted Trends
Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiological Insights- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Respiratory Syncytial Virus Marketed Drugs
• SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI):
Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of Respiratory Syncytial Virus. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by Respiratory Syncytial Virus in pediatric patients in the US.
Respiratory Syncytial Virus Emerging Drugs
Respiratory Syncytial ViruspreF (PF-06928316): Pfizer
Pfizer's investigational Respiratory Syncytial Virus vaccine candidate, Respiratory Syncytial ViruspreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that Respiratory Syncytial Virus uses to attack human cells. In March 2022, Pfizer announced that its Respiratory Syncytial Virus vaccine candidate, PF-06928316 or Respiratory Syncytial ViruspreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by Respiratory Syncytial Virus in individuals 60 years or older.
Respiratory Syncytial VirusPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
GSK3844766A contains a recombinant subunit pre-fusion Respiratory Syncytial Virus antigen combined with GSK's proprietary AS01 adjuvant, which is also used in the company's shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.
mRNA-1345: Moderna
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 Respiratory Syncytial Virus vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA's FTD for the Respiratory Syncytial Virus vaccine (mRNA-1345) in adults older than 60.
Respiratory Syncytial Virus Market Outlook
While understanding Respiratory Syncytial Virus pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for Respiratory Syncytial Virus infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.
Learn more about the FDA-approved drugs for Respiratory Syncytial Virus @ Respiratory Syncytial Virus Market Drivers and Barriers- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Respiratory Syncytial Virus Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Respiratory Syncytial Virus Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
• Respiratory Syncytial Virus Pipeline Therapies- Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others
• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus Market Drivers and Barriers
Discover more about Respiratory Syncytial Virus Drugs in development @ Respiratory Syncytial Virus Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Respiratory Syncytial Virus (RSV) Market Overview at a Glance
4. Executive Summary of Respiratory Syncytial Virus (RSV)
5. Key Events
6. Disease Background and Overview
7. Treatment and Management
8. Methodology
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Products
12. Emerging Therapies
13. Respiratory Syncytial Virus (RSV) Seven Major Market Analysis
14. Market Access and Reimbursement
15. RSV Reimbursement
16. KOL Views
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Respiratory Syncytial Virus Market Dynamics- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022 | Major Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others here
News-ID: 3138499 • Views: …
More Releases from DelveInsight Business Research
Head and Neck Cancer Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approval …
(New York, USA) DelveInsight's 'Head and Neck Cancer Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline head and neck cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the head and neck cancer pipeline domain.
Request for a free sample report @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Head and Neck Cancer Pipeline Report
• DelveInsight's…
Adenoid Cystic Carcinomas Pipeline Assessment (2024 Updates): FDA Approvals, Cli …
(Las Vegas, Nevada, United States)- As per DelveInsight's assessment, globally, about 5+ key Adenoid Cystic Carcinomas companies are working on 5+ pipeline drugs in the Adenoid Cystic Carcinomas therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Adenoid Cystic Carcinomas Pipeline Insight 2024"…
Infliximab Biosimilar Insight 2024: Clinical Trials, FDA Approvals, and Companie …
DelveInsight's "Infliximab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of Biosimilars,…
Wet Age-Related Macular Degeneration Market and Epidemiology 2032: Treatment Mar …
DelveInsight's "Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Wet Age-Related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click…
More Releases for Respiratory
Global Respiratory Devices and Equipment (Therapeutic) Market | Global Respirato …
The respiratory devices & equipment therapeutic market comprises of the sales of respiratory devices & equipment used for treating the patients with acute or chronic respiratory disorders for instance chronic obstructive pulmonary disease (COPD), sleep disorders, chronic bronchitis, asthma, etc. The market includes sales of respiratory monitoring devices establishments mainly engaged in the manufacturing of oxygen concentrators, nebulizers, humidifiers, positive airway pressure devices, ventilators, capnographs, and gas analyzers.
According to study,…
Global Respiratory Monitoring Devices Market | Global Respiratory Monitoring Dev …
Respiration is a unique process of human lives, which jumps at the time of birth and lasts till decease. A healthy human body is skilled of respiration process for numerous years but, due to rising levels of pollution in urban cities and lives concerning tobacco smoking, clogging of airways and other structures of the lung is turning into a common concern across the globe. The respiratory monitoring devices market comprises…
Middle East and Africa Respiratory InhalerMarket- AstraZeneca is advancing clini …
Recent Developments
AstraZeneca is multinational pharmaceutical and Biopharmaceutical Company. The company provides innovative medicines which are used by millions of people worldwide. AstraZeneca reduces the risk of death and disease progression. The company primarily focuses on development and discovery of cardiovascular, respiratory and inflammation, oncology and infectious disease.
To know more:https://www.marketdataforecast.com/market-reports/middle-east-and-africa-respiratory-inhaler-market-6377/
Market Segmentations:
Market Data Forecast published a report named Middle East and Africa Respiratory InhalerMarket. It is estimated to grow at a robust…
Respiratory Devices Analysis Report of Respiratory Devices in Global Market 2018 …
- Global Respiratory Devices Market: Overview
Respiratory devices are medical equipment that assist patients with respiration in a critical care situation. Additionally, respiratory devices are used to deliver medicines to treat several respiratory diseases. Moreover, these devices are used to diagnose respiratory problems in patients. Increase in incidence of COPD and sleep apnea, strategic alliance between key players, and rise in government expenditure are the major factors projected to propel the…
Neonatal Respiratory Distress Syndrome Market is driven by high prevalence of re …
Neonatal respiratory distress syndrome, also referred to as infant respiratory distress syndrome is characterized by a particular condition often observed in premature babies, usually born about six weeks before their due dates. During this condition, lungs of the premature infants lose the ability to produce enough surfactants in order to provide oxygen to the body. Surfactants are liquids made up of fat and proteins and it helps the lungs to…
Global Respiratory Monitoring Devices Market to Benefit from Increasing Prevalen …
Respiratory disease is a serious public health concern due to rapidly growing number of smokers worldwide. Governments are implementing various health schemes to reduce the death rate caused due to respiratory disease and disorders. Respiratory disease is a medical condition that affects the structure and organs (respiratory system) associated with respiration or breathing.
Rise in respiratory diseases such as chronic obstructive pulmonary diseases, asthma, and lung cancer has triggered the growth…
